Dr. Scott L. Friedman is the Dean for Therapeutic Discovery and Chief of the Division of Liver Diseases at the Icahn School of Medicine at Mount Sinai. He has performed pioneering research into the underlying causes of liver scarring, or fibrosis associated with chronic liver disease, affecting millions worldwide. Dr. Friedman was among the first to isolate and characterize the hepatic stellate cell, the key cell type responsible for scar production in liver. His work has spawned an entire field that is now realizing its translational and therapeutic potential, with new anti-fibrotic and NASH therapies for liver disease reaching clinical trials. Dr. Friedman’s work has been continuously funded by the NIH since 1985, and has authored over 300 peer-reviewed publications.
Dr. Friedman was a recipient in 1993 of the Saul Horowitz, Jr. Outstanding Alumnus Award from Mount Sinai. In 2003, Dr. Friedman was honored with the International Hans Popper Award by the Falk Foundation in Freiburg, Germany, in recognition of his outstanding contributions to the understanding of liver disease and its treatment. In 2012, he was awarded the European Association for the Study of Liver Diseases International Recognition Award in Barcelona, Spain, and in 2013 he was awarded the Shanghai Magnolia Gold Award by the Mayor of Shanghai and the China Friendship Award from the Premier of China in 2014, in recognition of his efforts to improve the health of the residents of Shanghai and China through his research achievements. In 2016, he was awarded the Distinguished Achievement Awards from both the AASLD and the American Liver Foundation.
As President of the American Assn. for the Study of Liver Diseases in 2009, Dr. Friedman oversaw several major new initiatives that accelerated its growth and brought the Association to new levels of income and international visibility.
Dr. Friedman’s appointment in 2012 as Dean for Therapeutic Discovery at Mount Sinai recognizes his unique strengths in translating basic science into clinically meaningful advances, and his investigative work in liver disease has been instrumental in fueling the tremendous growth in emerging diagnostics and therapeutics for hepatic fibrosis.